We are excited to announce our new immunotoxicity service; the peripheral blood mononuclear cell (PBMC) cytotoxicity assay. This service assesses the cytotoxic potential of candidate drugs towards PBMC and can be followed up with a variety of further studies with additional endpoints, offering further insights into the mechanisms of drug-mediated hypersensitivity.
We also have several other services in development to assist with the prediction of immunotoxicity in early drug development. Find out more about this area by clicking the link below, or contact us to make an enquiry:
Our latest blog, “Oral Dose Pharmacokinetic Profiling for Early Drug Discovery”, explores the most recent additions to our PK prediction services. Click below to find out more, or watch the webinar to learn more about our work in using ADME data to predict human PK parameters.